Please login to the form below

Not currently logged in

Depression can raise cancer death rates

A study has found that in patients with cancer, death rates were up to 25 per cent higher in those showing symptoms of depression

A study by the University of British Columbia has found that in patients with cancer, death rates were up to 25 per cent higher in those showing symptoms of depression. In patients actually diagnosed with major or minor depression, death rates were up to 39 per cent higher.

The study, a review of 26 separate studies, included 9,417 patients. The researchers said, however, that more research was needed regarding the impact of other factors, before any definitive conclusions were made, and that from the very limited studies carried out, they could find no firm evidence that depression impacted on the progression of the disease.

Theories as to why depression impacts on survival rates include the conjecture that it impacts on hormones or the immune system, or that depressed people may be less likely to comply with treatment regimens.

Lead researcher Jillian Satin said: "It is quite remarkable that the presence of depressive symptoms or a diagnosis of a depressive disorder can predict mortality in cancer patients." However, he added that "it should be kept in mind that the increased risk is quite small".

Dr Julie Sharp, of Cancer Research UK, said: "This research adds weight to the importance of identifying depression early in people with cancer and offering them appropriate support and care." She added: "The effects observed in this study are quite small and may be due to other factors. More research will be needed to explain whether these observations are true and if so why."

14th September 2009


Featured jobs

Subscribe to our email news alerts


Add my company

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....